Traws Pharma (TRAW) investor relations material

Executive summary

• Report covers the quarter ended March 31, 2026, for a clinical-stage biopharmaceutical company focused on respiratory viral diseases and oncology programs.

• Four clinical programs are in development, with primary focus on tivoxavir marboxil (TXM) and ratutrelvir; oncology assets are being positioned for partnerships.

• Secured up to $60M in private financing, with $10M upfront and milestone-based warrants, extending operational runway into Q1 2027.

• Advanced TXM toward a human influenza challenge trial as a once-monthly prophylactic, with trial initiation planned for Q2 2026.

• Progressed clinical candidate for hantavirus treatment, responding to recent outbreaks and unmet medical need.

Financial highlights

• Revenue for Q1 2026 was $0.0M, down from $0.06M in Q1 2025.

• Net loss for Q1 2026 was $7.1M, compared to net income of $21.5M in Q1 2025 (prior year included a $26.5M gain from warrant liability remeasurement).

• R&D expenses rose 96% year-over-year to $4.9M, driven by virology program advancement and higher stock-based compensation.

• G&A expenses decreased to $2.0M in Q1 2026 from $2.8M in Q1 2025, primarily due to lower professional and consulting fees.

• Cash and cash equivalents at March 31, 2026, were $3.1M, with a working capital deficit of $7.9M.

Outlook and guidance

• Current cash, including April 2026 financing proceeds and warrants, is not sufficient to fund operations for 12 months; substantial doubt exists about ability to continue as a going concern.

• Additional financing will be required to support ongoing trials and operations.

• Plans to resolve FDA clinical hold on TXM and initiate global clinical studies by year-end 2026.

• Rapid advancement of hantavirus clinical candidate in response to recent outbreaks.